4.7 Review

Potential effects of curcumin in the treatment ofCOVID-19 infection

期刊

PHYTOTHERAPY RESEARCH
卷 34, 期 11, 页码 2911-2920

出版社

WILEY
DOI: 10.1002/ptr.6738

关键词

acute respiratory distress syndrome; curcuminoids; pulmonary fibrosis; viral infection

资金

  1. Amgen
  2. Angelini
  3. Astra Zeneca
  4. Boehringer Ingelheim
  5. Galenica
  6. MSD
  7. Novartis
  8. Novo Nordisk
  9. Sanofi
  10. WinMedica

向作者/读者索取更多资源

Coronavirus disease 2019 (COVID-19) outbreak is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with considerable mortality worldwide. The main clinical manifestation of COVID-19 is the presence of respiratory symptoms, but some patients develop severe cardiovascular and renal complications. There is an urgency to understand the mechanism by which this virus causes complications so as to develop treatment options. Curcumin, a natural polyphenolic compound, could be a potential treatment option for patients with coronavirus disease. In this study, we review some of the potential effects of curcumin such as inhibiting the entry of virus to the cell, inhibiting encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. This review provides a basis for further research and development of clinical applications of curcumin for the treatment of newly emerged SARS-CoV-2.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据